Quarterly report [Sections 13 or 15(d)]

Asset Purchase and Merger Agreements - Checkpoint Transaction (Details)

v3.26.1
Asset Purchase and Merger Agreements - Checkpoint Transaction (Details) - USD ($)
1 Months Ended 3 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Business Combination [Line Items]        
Gain from deconsolidation of subsidiary     $ 27,100,000  
Revenue     15,921,000 $ 13,139,000
Checkpoint Merger        
Business Combination [Line Items]        
Proceeds from sale of subsidiary interests $ 28,000,000      
Royalty revenue        
Business Combination [Line Items]        
Revenue     77,000  
Checkpoint Merger        
Business Combination [Line Items]        
Milestone paid     $ 0  
Checkpoint Merger | Checkpoint Merger | Sun Pharmaceutical Industries, Inc.        
Business Combination [Line Items]        
Stock purchase, price per share   $ 4.1   $ 4.1
Maximum contingent consideration per each outstanding share   $ 0.7   $ 0.7
Checkpoint Merger | Royalty revenue        
Business Combination [Line Items]        
Percentage of royalty on future net sales   2.50%